The global Cardioselective Beta Blockers market size was valued at US$ 7199 million in 2024 and is forecast to a readjusted size of USD 10750 million by 2031 with a CAGR of 6.0% during review period.
Cardioselective beta blockers intercept the activation of beta-1 adrenergic receptors present at the nerve endings of the sympathetic nervous system. This eventually results in diminished activity of the heart, such as a reduction in systolic pressure, heart rate and cardiac contractility. Cardioselective agents have a better affinity for 尾1-adrenergic receptors located in the heart, whereas nonselective agents work on 尾1-adrenergic receptors and 尾2-adrenergic receptors located in bronchial musculature.
Widespread Demand for Metoprolol for Cardiovascular Diseases: Treatment of Cardiovascular Diseases with Metoprolol presents a huge revenue opportunity for companies in the market. The metoprolol segment holds the dominant market share in pharmaceuticals in 2022. Outstanding safety and efficacy, ease of administration, and affordability are key factors for the widespread utilization of this class of drugs in the treatment of heart failure and hypertension. Surging demand for metoprolol over the past few years is likely to drive the market in the near future.
Development of drug delivery technologies to improve the safety and efficacy of cardioselective beta-blockers: Ongoing research into the mechanism of action of beta-blockers enables the company to develop drugs with unique pharmacological profiles. This may facilitate the off-label use of beta-blockers and provide new business opportunities for drug manufacturers in the near future. In addition, pharmaceutical companies are working to develop beta-blockers with improved routes of administration to reduce their common side effects and enhance the targeting of these drugs in the treatment of angina, cardiac arrhythmias, and chronic heart failure.
This report is a detailed and comprehensive analysis for global Cardioselective Beta Blockers market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Cardioselective Beta Blockers market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031
Global Cardioselective Beta Blockers market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031
Global Cardioselective Beta Blockers market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031
Global Cardioselective Beta Blockers market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Cardioselective Beta Blockers
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Cardioselective Beta Blockers market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include F. Hoffmann-La Roche Ltd, Fresenius Kabi AG, Pfizer Inc, Bayer AG, GSK Plc, Sanofi, Novartis AG, Mylan N.V, Teva Pharmaceutical Industries Ltd, Zydus Group, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
麻豆原创 Segmentation
Cardioselective Beta Blockers market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
麻豆原创 segment by Type
Oral
Injection
麻豆原创 segment by Application
Hospitals
Specialty Clinics
Other
Major players covered
F. Hoffmann-La Roche Ltd
Fresenius Kabi AG
Pfizer Inc
Bayer AG
GSK Plc
Sanofi
Novartis AG
Mylan N.V
Teva Pharmaceutical Industries Ltd
Zydus Group
Viatris Inc
Merck & Co., Inc
Recordati S.p.A
Pierre Fabre Group
AbbVie, Inc
AstraZeneca
麻豆原创 segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Cardioselective Beta Blockers product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Cardioselective Beta Blockers, with price, sales quantity, revenue, and global market share of Cardioselective Beta Blockers from 2020 to 2025.
Chapter 3, the Cardioselective Beta Blockers competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Cardioselective Beta Blockers breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2020 to 2031.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2020 to 2031.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2020 to 2025.and Cardioselective Beta Blockers market forecast, by regions, by Type, and by Application, with sales and revenue, from 2026 to 2031.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Cardioselective Beta Blockers.
Chapter 14 and 15, to describe Cardioselective Beta Blockers sales channel, distributors, customers, research findings and conclusion.
Please Note - This is an on demand report and will be delivered in 2 business days (48 Hours) post payment.
1 麻豆原创 Overview
1.1 Product Overview and Scope
1.2 麻豆原创 Estimation Caveats and Base Year
1.3 麻豆原创 Analysis by Type
1.3.1 Overview: Global Cardioselective Beta Blockers Consumption Value by Type: 2020 Versus 2024 Versus 2031
1.3.2 Oral
1.3.3 Injection
1.4 麻豆原创 Analysis by Application
1.4.1 Overview: Global Cardioselective Beta Blockers Consumption Value by Application: 2020 Versus 2024 Versus 2031
1.4.2 Hospitals
1.4.3 Specialty Clinics
1.4.4 Other
1.5 Global Cardioselective Beta Blockers 麻豆原创 Size & Forecast
1.5.1 Global Cardioselective Beta Blockers Consumption Value (2020 & 2024 & 2031)
1.5.2 Global Cardioselective Beta Blockers Sales Quantity (2020-2031)
1.5.3 Global Cardioselective Beta Blockers Average Price (2020-2031)
2 Manufacturers Profiles
2.1 F. Hoffmann-La Roche Ltd
2.1.1 F. Hoffmann-La Roche Ltd Details
2.1.2 F. Hoffmann-La Roche Ltd Major Business
2.1.3 F. Hoffmann-La Roche Ltd Cardioselective Beta Blockers Product and Services
2.1.4 F. Hoffmann-La Roche Ltd Cardioselective Beta Blockers Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.1.5 F. Hoffmann-La Roche Ltd Recent Developments/Updates
2.2 Fresenius Kabi AG
2.2.1 Fresenius Kabi AG Details
2.2.2 Fresenius Kabi AG Major Business
2.2.3 Fresenius Kabi AG Cardioselective Beta Blockers Product and Services
2.2.4 Fresenius Kabi AG Cardioselective Beta Blockers Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.2.5 Fresenius Kabi AG Recent Developments/Updates
2.3 Pfizer Inc
2.3.1 Pfizer Inc Details
2.3.2 Pfizer Inc Major Business
2.3.3 Pfizer Inc Cardioselective Beta Blockers Product and Services
2.3.4 Pfizer Inc Cardioselective Beta Blockers Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.3.5 Pfizer Inc Recent Developments/Updates
2.4 Bayer AG
2.4.1 Bayer AG Details
2.4.2 Bayer AG Major Business
2.4.3 Bayer AG Cardioselective Beta Blockers Product and Services
2.4.4 Bayer AG Cardioselective Beta Blockers Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.4.5 Bayer AG Recent Developments/Updates
2.5 GSK Plc
2.5.1 GSK Plc Details
2.5.2 GSK Plc Major Business
2.5.3 GSK Plc Cardioselective Beta Blockers Product and Services
2.5.4 GSK Plc Cardioselective Beta Blockers Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.5.5 GSK Plc Recent Developments/Updates
2.6 Sanofi
2.6.1 Sanofi Details
2.6.2 Sanofi Major Business
2.6.3 Sanofi Cardioselective Beta Blockers Product and Services
2.6.4 Sanofi Cardioselective Beta Blockers Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.6.5 Sanofi Recent Developments/Updates
2.7 Novartis AG
2.7.1 Novartis AG Details
2.7.2 Novartis AG Major Business
2.7.3 Novartis AG Cardioselective Beta Blockers Product and Services
2.7.4 Novartis AG Cardioselective Beta Blockers Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.7.5 Novartis AG Recent Developments/Updates
2.8 Mylan N.V
2.8.1 Mylan N.V Details
2.8.2 Mylan N.V Major Business
2.8.3 Mylan N.V Cardioselective Beta Blockers Product and Services
2.8.4 Mylan N.V Cardioselective Beta Blockers Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.8.5 Mylan N.V Recent Developments/Updates
2.9 Teva Pharmaceutical Industries Ltd
2.9.1 Teva Pharmaceutical Industries Ltd Details
2.9.2 Teva Pharmaceutical Industries Ltd Major Business
2.9.3 Teva Pharmaceutical Industries Ltd Cardioselective Beta Blockers Product and Services
2.9.4 Teva Pharmaceutical Industries Ltd Cardioselective Beta Blockers Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.9.5 Teva Pharmaceutical Industries Ltd Recent Developments/Updates
2.10 Zydus Group
2.10.1 Zydus Group Details
2.10.2 Zydus Group Major Business
2.10.3 Zydus Group Cardioselective Beta Blockers Product and Services
2.10.4 Zydus Group Cardioselective Beta Blockers Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.10.5 Zydus Group Recent Developments/Updates
2.11 Viatris Inc
2.11.1 Viatris Inc Details
2.11.2 Viatris Inc Major Business
2.11.3 Viatris Inc Cardioselective Beta Blockers Product and Services
2.11.4 Viatris Inc Cardioselective Beta Blockers Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.11.5 Viatris Inc Recent Developments/Updates
2.12 Merck & Co., Inc
2.12.1 Merck & Co., Inc Details
2.12.2 Merck & Co., Inc Major Business
2.12.3 Merck & Co., Inc Cardioselective Beta Blockers Product and Services
2.12.4 Merck & Co., Inc Cardioselective Beta Blockers Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.12.5 Merck & Co., Inc Recent Developments/Updates
2.13 Recordati S.p.A
2.13.1 Recordati S.p.A Details
2.13.2 Recordati S.p.A Major Business
2.13.3 Recordati S.p.A Cardioselective Beta Blockers Product and Services
2.13.4 Recordati S.p.A Cardioselective Beta Blockers Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.13.5 Recordati S.p.A Recent Developments/Updates
2.14 Pierre Fabre Group
2.14.1 Pierre Fabre Group Details
2.14.2 Pierre Fabre Group Major Business
2.14.3 Pierre Fabre Group Cardioselective Beta Blockers Product and Services
2.14.4 Pierre Fabre Group Cardioselective Beta Blockers Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.14.5 Pierre Fabre Group Recent Developments/Updates
2.15 AbbVie, Inc
2.15.1 AbbVie, Inc Details
2.15.2 AbbVie, Inc Major Business
2.15.3 AbbVie, Inc Cardioselective Beta Blockers Product and Services
2.15.4 AbbVie, Inc Cardioselective Beta Blockers Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.15.5 AbbVie, Inc Recent Developments/Updates
2.16 AstraZeneca
2.16.1 AstraZeneca Details
2.16.2 AstraZeneca Major Business
2.16.3 AstraZeneca Cardioselective Beta Blockers Product and Services
2.16.4 AstraZeneca Cardioselective Beta Blockers Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.16.5 AstraZeneca Recent Developments/Updates
3 Competitive Environment: Cardioselective Beta Blockers by Manufacturer
3.1 Global Cardioselective Beta Blockers Sales Quantity by Manufacturer (2020-2025)
3.2 Global Cardioselective Beta Blockers Revenue by Manufacturer (2020-2025)
3.3 Global Cardioselective Beta Blockers Average Price by Manufacturer (2020-2025)
3.4 麻豆原创 Share Analysis (2024)
3.4.1 Producer Shipments of Cardioselective Beta Blockers by Manufacturer Revenue ($MM) and 麻豆原创 Share (%): 2024
3.4.2 Top 3 Cardioselective Beta Blockers Manufacturer 麻豆原创 Share in 2024
3.4.3 Top 6 Cardioselective Beta Blockers Manufacturer 麻豆原创 Share in 2024
3.5 Cardioselective Beta Blockers 麻豆原创: Overall Company Footprint Analysis
3.5.1 Cardioselective Beta Blockers 麻豆原创: Region Footprint
3.5.2 Cardioselective Beta Blockers 麻豆原创: Company Product Type Footprint
3.5.3 Cardioselective Beta Blockers 麻豆原创: Company Product Application Footprint
3.6 New 麻豆原创 Entrants and Barriers to 麻豆原创 Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
4.1 Global Cardioselective Beta Blockers 麻豆原创 Size by Region
4.1.1 Global Cardioselective Beta Blockers Sales Quantity by Region (2020-2031)
4.1.2 Global Cardioselective Beta Blockers Consumption Value by Region (2020-2031)
4.1.3 Global Cardioselective Beta Blockers Average Price by Region (2020-2031)
4.2 North America Cardioselective Beta Blockers Consumption Value (2020-2031)
4.3 Europe Cardioselective Beta Blockers Consumption Value (2020-2031)
4.4 Asia-Pacific Cardioselective Beta Blockers Consumption Value (2020-2031)
4.5 South America Cardioselective Beta Blockers Consumption Value (2020-2031)
4.6 Middle East & Africa Cardioselective Beta Blockers Consumption Value (2020-2031)
5 麻豆原创 Segment by Type
5.1 Global Cardioselective Beta Blockers Sales Quantity by Type (2020-2031)
5.2 Global Cardioselective Beta Blockers Consumption Value by Type (2020-2031)
5.3 Global Cardioselective Beta Blockers Average Price by Type (2020-2031)
6 麻豆原创 Segment by Application
6.1 Global Cardioselective Beta Blockers Sales Quantity by Application (2020-2031)
6.2 Global Cardioselective Beta Blockers Consumption Value by Application (2020-2031)
6.3 Global Cardioselective Beta Blockers Average Price by Application (2020-2031)
7 North America
7.1 North America Cardioselective Beta Blockers Sales Quantity by Type (2020-2031)
7.2 North America Cardioselective Beta Blockers Sales Quantity by Application (2020-2031)
7.3 North America Cardioselective Beta Blockers 麻豆原创 Size by Country
7.3.1 North America Cardioselective Beta Blockers Sales Quantity by Country (2020-2031)
7.3.2 North America Cardioselective Beta Blockers Consumption Value by Country (2020-2031)
7.3.3 United States 麻豆原创 Size and Forecast (2020-2031)
7.3.4 Canada 麻豆原创 Size and Forecast (2020-2031)
7.3.5 Mexico 麻豆原创 Size and Forecast (2020-2031)
8 Europe
8.1 Europe Cardioselective Beta Blockers Sales Quantity by Type (2020-2031)
8.2 Europe Cardioselective Beta Blockers Sales Quantity by Application (2020-2031)
8.3 Europe Cardioselective Beta Blockers 麻豆原创 Size by Country
8.3.1 Europe Cardioselective Beta Blockers Sales Quantity by Country (2020-2031)
8.3.2 Europe Cardioselective Beta Blockers Consumption Value by Country (2020-2031)
8.3.3 Germany 麻豆原创 Size and Forecast (2020-2031)
8.3.4 France 麻豆原创 Size and Forecast (2020-2031)
8.3.5 United Kingdom 麻豆原创 Size and Forecast (2020-2031)
8.3.6 Russia 麻豆原创 Size and Forecast (2020-2031)
8.3.7 Italy 麻豆原创 Size and Forecast (2020-2031)
9 Asia-Pacific
9.1 Asia-Pacific Cardioselective Beta Blockers Sales Quantity by Type (2020-2031)
9.2 Asia-Pacific Cardioselective Beta Blockers Sales Quantity by Application (2020-2031)
9.3 Asia-Pacific Cardioselective Beta Blockers 麻豆原创 Size by Region
9.3.1 Asia-Pacific Cardioselective Beta Blockers Sales Quantity by Region (2020-2031)
9.3.2 Asia-Pacific Cardioselective Beta Blockers Consumption Value by Region (2020-2031)
9.3.3 China 麻豆原创 Size and Forecast (2020-2031)
9.3.4 Japan 麻豆原创 Size and Forecast (2020-2031)
9.3.5 South Korea 麻豆原创 Size and Forecast (2020-2031)
9.3.6 India 麻豆原创 Size and Forecast (2020-2031)
9.3.7 Southeast Asia 麻豆原创 Size and Forecast (2020-2031)
9.3.8 Australia 麻豆原创 Size and Forecast (2020-2031)
10 South America
10.1 South America Cardioselective Beta Blockers Sales Quantity by Type (2020-2031)
10.2 South America Cardioselective Beta Blockers Sales Quantity by Application (2020-2031)
10.3 South America Cardioselective Beta Blockers 麻豆原创 Size by Country
10.3.1 South America Cardioselective Beta Blockers Sales Quantity by Country (2020-2031)
10.3.2 South America Cardioselective Beta Blockers Consumption Value by Country (2020-2031)
10.3.3 Brazil 麻豆原创 Size and Forecast (2020-2031)
10.3.4 Argentina 麻豆原创 Size and Forecast (2020-2031)
11 Middle East & Africa
11.1 Middle East & Africa Cardioselective Beta Blockers Sales Quantity by Type (2020-2031)
11.2 Middle East & Africa Cardioselective Beta Blockers Sales Quantity by Application (2020-2031)
11.3 Middle East & Africa Cardioselective Beta Blockers 麻豆原创 Size by Country
11.3.1 Middle East & Africa Cardioselective Beta Blockers Sales Quantity by Country (2020-2031)
11.3.2 Middle East & Africa Cardioselective Beta Blockers Consumption Value by Country (2020-2031)
11.3.3 Turkey 麻豆原创 Size and Forecast (2020-2031)
11.3.4 Egypt 麻豆原创 Size and Forecast (2020-2031)
11.3.5 Saudi Arabia 麻豆原创 Size and Forecast (2020-2031)
11.3.6 South Africa 麻豆原创 Size and Forecast (2020-2031)
12 麻豆原创 Dynamics
12.1 Cardioselective Beta Blockers 麻豆原创 Drivers
12.2 Cardioselective Beta Blockers 麻豆原创 Restraints
12.3 Cardioselective Beta Blockers Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
13 Raw Material and Industry Chain
13.1 Raw Material of Cardioselective Beta Blockers and Key Manufacturers
13.2 Manufacturing Costs Percentage of Cardioselective Beta Blockers
13.3 Cardioselective Beta Blockers Production Process
13.4 Industry Value Chain Analysis
14 Shipments by Distribution Channel
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Cardioselective Beta Blockers Typical Distributors
14.3 Cardioselective Beta Blockers Typical Customers
15 Research Findings and Conclusion
16 Appendix
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
F. Hoffmann-La Roche Ltd
Fresenius Kabi AG
Pfizer Inc
Bayer AG
GSK Plc
Sanofi
Novartis AG
Mylan N.V
Teva Pharmaceutical Industries Ltd
Zydus Group
Viatris Inc
Merck & Co., Inc
Recordati S.p.A
Pierre Fabre Group
AbbVie, Inc
AstraZeneca
听
听
*If Applicable.
